“Kratom Is an Opioid”: Grassley, Seven Senators Demand Answers Over Weakened Federal Restrictions
The signers chair the committees that write the laws and budgets for DEA and FDA, and they want the 7-OH rollback reversed.

Senate Judiciary Chairman Chuck Grassley (R-Iowa) and seven Republican colleagues are demanding that DEA and FDA explain why they loosened the rules on two kratom-derived opioids. The Grassley kratom letter, released this week, opens with four words: “Kratom is an opioid.”
Who signed the Grassley kratom letter
Grassley chairs the Judiciary Committee, which oversees DEA and the Justice Department.
Sen. Susan Collins (R-Maine) chairs the full Appropriations Committee, which writes the federal budget.
Get stories like this every Friday
The week's drug policy news in one email, every claim sourced. Join tens of thousands of readers.
Sen. Jerry Moran (R-Kan.) chairs the Appropriations subcommittee on Commerce, Justice and Science, which funds DEA and DOJ. His panel’s new spending bill orders DEA to brief Congress on the health and safety impacts of kratom.
Sen. Shelley Moore Capito (R-W.Va.) chairs the Labor, Health and Human Services appropriations subcommittee, which funds HHS.
Sen. Bill Cassidy (R-La.) chairs the Health, Education, Labor and Pensions (HELP) Committee, which has jurisdiction over FDA.
The rest of the list carries weight too. Sen. Mike Crapo (R-Idaho) chairs the Finance Committee, and Sen. Jim Risch (R-Idaho) leads Foreign Relations. Finally, Sen. Rick Scott (R-Fla.) chairs the Special Committee on Aging.
What changed, and what the senators want
In July, DEA moved to place 7-OH in Schedule I above 0.05 percent. It also moved to ban mitragynine pseudoindoxyl (MP), a semi-synthetic kratom opioid, and placed it in Schedule I with no threshold in August.
Then in October, after a revised recommendation from HHS, DEA rewrote the plan. Specifically, the new proposal doubles the 7-OH limit to 0.1 percent and lets MP stay in products sold as “natural” kratom below the same line. The letter says DEA ended up “setting a more permissive 7-OH limit.”
In the kratom letter, the senators describe MP as a synthetic opioid more potent than morphine. As a result, they ask FDA to hand over the evaluations behind the higher threshold. They also urge DEA to return to its original July threshold for 7-OH and to place MP in Schedule I.
“Natural” does not mean safe
The letter takes direct aim at the industry’s favorite distinction. “Surely artificially enhanced Kratom products are often more dangerous, but that does not mean that so-called ‘natural’ ones are safe,” the senators wrote.
To back that up, the Grassley kratom letter cites a recent journal editorial by opioid expert Dr. Andrew Kolodny and poison center director Dr. Christopher Holstege, which argues that kratom itself is an opioid. “Kratom is a drug in any form with addictive properties,” the letter adds.
Meanwhile, the rollback followed an industry lobbying campaign. The New York Times reported that a kratom distributor facing wrongful death suits pressed the administration to allow MP. CDC data tie kratom to at least 5,208 overdose deaths from 2020 to 2024.
This is Grassley’s second kratom letter in six weeks. Earlier, in October, he joined Sens. Mike Lee and Collins in asking DEA and FDA to schedule the entire kratom plant.
“The American people deserve peace of mind about what is sold on marketplace shelves,” the senators wrote. This time, the people asking control the agencies’ budgets.
Get The Drug Report every Friday
One free email every Friday: the week's drug policy news, sourced and explained. Read by tens of thousands of people who write, enforce and cover the policy. Unsubscribe anytime.
